News & Events

Press Releases

2025

September 02, 2025
Encoded Therapeutics Announces Regenerative Medicine Advanced Therapy (RMAT) Designation Granted by U.S. FDA for ETX101 in SCN1A+ Dravet Syndrome
May 13, 2025
Encoded Therapeutics Presents Promising New Data for CNS Gene Therapy Programs at the ASGCT 28th Annual Meeting
April 28, 2025
Encoded Therapeutics to Present New Data for CNS Gene Therapy Programs at the ASGCT 28th Annual Meeting
February 13, 2025
Encoded Therapeutics Reports Clinical Progress of ETX101 Gene Therapy for Dravet Syndrome, Recaps 2024 Corporate Achievements and Provides 2025 Outlook

2024

November 07, 2024
Encoded Demonstrates Therapeutic Potential of a Vectorized miRNA-based Approach for Angelman Syndrome at the FAST Annual Global Science Summit
May 07, 2024
Encoded Therapeutics Presents Preclinical Data Across its Gene Therapy Portfolio at the 27th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
April 23, 2024
Encoded Therapeutics Provides Pipeline Updates From Its Vector Engineering Platform Ahead of Four Preclinical Presentations at the 27th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
February 26, 2024
Encoded Therapeutics Announces UK CTA Approval for Dravet Syndrome Gene Therapy Candidate ETX101
February 06, 2024
Encoded Therapeutics Announces US IND Clearance and Australian CTA Approval for Dravet Syndrome Gene Therapy Candidate ETX101

2023

May 19, 2023
Encoded Therapeutics Addresses Common Source of Gene Therapy Toxicity While Achieving Precise Brain Expression in Non-Human Primates, Presented at the American Society of Gene and Cell Therapy 26th Annual Meeting

2022

May 18, 2022
Encoded Therapeutics Presents Nonclinical Data Showing Genomic Medicine Platform Yields Selective Expression to Optimize Gene Therapy Performance at the American Society of Gene and Cell Therapy 25th Annual Meeting
May 02, 2022
Encoded Therapeutics to Present Nonclinical Data Showing Targeted Brain Expression While De-Targeting the Liver With Genomic Medicine Platform at the American Society of Gene and Cell Therapy 25th Annual Meeting

2021

December 03, 2021
Encoded Therapeutics Presents Data Showing That Children With Dravet Syndrome Experience Early, Substantial Neurodevelopment Deficits and Seizure Burden, at the American Epilepsy Society 2021 Annual Meeting
November 23, 2021
Encoded Therapeutics to Present Initial ENVISION Natural History Study Data of Children With SCN1A+ Dravet Syndrome at the American Epilepsy Society (AES) 2021 Annual Meeting

2020

July 22, 2020
Encoded Therapeutics Announces $135 Million Series D Financing to Support First Clinical Trials in SCN1A+ Dravet Syndrome and Advance Preclinical Pipeline of Gene Therapies for Debilitating Neurological Disorders
February 11, 2020
Encoded Therapeutics Expands Gene Therapy Leadership with Key Appointment and Promotion

2019

December 18, 2019
Encoded Therapeutics Strengthens Senior Leadership Team with Key Appointments in Regulatory and Human Resources Functions
September 17, 2019
Encoded Therapeutics Expands Leadership Team with Key Appointments, Adding Expertise in Manufacturing and Corporate Development
June 26, 2019
Encoded Therapeutics, Inc. Announces $104 Million Series C Financing to Advance Lead Gene Therapy Program in Dravet Syndrome and Unveils its Precision Gene Therapy Platform